TickerFacts.

Metagenomi Therapeutics, Inc. (MGX): Revenue

Annual figures by period end, from SEC filings.

$25.21M
Year ended 2025-12-31
$52.30M2023-12-31: $44.76M2024-12-31: $52.30M2025-12-31: $25.21M$25.21M
2023-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$25.21M-51.8%2026-03-05, From 2025-01-01
2024-12-31$52.30M+16.8%2026-03-05, From 2024-01-01
2023-12-31$44.76Mn/a2025-03-17, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Metagenomi Therapeutics, Inc. (MGX)2025-12-31$25.21M-51.8%
Alector, Inc. (ALEC)2025-12-31$21.05M-79.1%
Scilex Holding Co (SCLX)2025-12-31$30.25M-46.5%
LENZ Therapeutics, Inc. (LENZ)2025-12-31$19.09Mn/a
Precision Biosciences Inc (DTIL)2025-12-31$34.26M-50.1%
X4 Pharmaceuticals, Inc (XFOR)2025-12-31$35.11Mn/m
C4 Therapeutics, Inc. (CCCC)2025-12-31$35.95M+1.0%
Pelthos Therapeutics Inc. (PTHS)2025-12-31$16.80Mn/a
Kymera Therapeutics, Inc. (KYMR)2025-12-31$39.21M-16.7%

Compare MGX, ALEC, SCLX, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗